Deborah E. Citrin, M.D.
Radiation Oncology Branch
Building 10 - Hatfield CRC, Room B2-3500
Bethesda, MD 20892
Dr. Citrin's research interests include the pre-clinical and clinical testing of radiation modifiers and the mechanisms of normal tissue injury from radiation. Dr. Citrin is involved in the clinical care of patients with genitourinary cancers (prostate and bladder), gastrointestinal cancers, and melanoma.
Dr. Citrin is a clinician and translational researcher in the Radiation Oncology Branch at NCI. She is a graduate of the Duke University School of Medicine and completed her residency training at NCI and the National Capital Consortium. She joined the NIH in 2001. Her research interests include the pre-clinical and clinical testing of radiation modifiers and the mechanisms of normal tissue injury from radiation. Dr. Citrin is involved in the clinical care of patients with genitourinary cancers (prostate and bladder) and gastrointestinal cancers. Dr. Citrin is board certified by the American Board of Radiology.
Chung SI, Horton JA, Ramalingam TR, White AO, Chung EJ, Hudak KE, Scroggins BT, Arron JR, Wynn TA, Citrin DE. IL-13 is a therapeutic target in radiation lung injury. Sci Rep. 2016;6:39714.
Horton JA, Hudak KE, Chung EJ, White AO, Scroggins BT, Burkeen JF, Citrin DE. Mesenchymal stem cells inhibit cutaneous radiation-induced fibrosis by suppressing chronic inflammation. Stem Cells. 2013;31(10):2231-41.
Citrin DE, Shankavaram U, Horton JA, Shield W 3rd, Zhao S, Asano H, White A, Sowers A, Thetford A, Chung EJ. Role of type II pneumocyte senescence in radiation-induced lung fibrosis. J Natl Cancer Inst. 2013;105(19):1474-84.
Urick ME, Chung EJ, Shield WP 3rd, Gerber N, White A, Sowers A, Thetford A, Camphausen K, Mitchell J, Citrin DE. Enhancement of 5-fluorouracil-induced in vitro and in vivo radiosensitization with MEK inhibition. Clin Cancer Res. 2011;17(15):5038-47.
Chung EJ, Brown AP, Asano H, Mandler M, Burgan WE, Carter D, Camphausen K, Citrin D. In vitro and in vivo radiosensitization with AZD6244 (ARRY-142886), an inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 kinase. Clin Cancer Res. 2009;15(9):3050-7.
Related Scientific Focus Areas
Molecular Biology and Biochemistry
This page was last updated on April 30th, 2019